EGFR and neoplasm: Furthermore, anti‐EGRF‐affibody was conjugated to PEGylated TiO2–UCNPs nanocomposites for targeting epithelial growth factor receptor (EGFR) overexpressing oral cancer cells and the subsequent NIR‐excited PDT with the therapeutic outcome of significantly suppressed tumor growth and improved survival rate of tumor‐bearing mice.104